Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)

被引：0
|
作者：
Woerle, H. J. [1 ]
Neubacher, D. [2 ]
Patel, S. [3 ]
von Eynatten, M. [1 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[3] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2013年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
    Tonoike, Mie
    Chujo, Daisuke
    Noda, Mitsuhiko
    ENDOCRINOLOGY DIABETES & METABOLISM, 2019, 2 (01)
  • [22] Evaluation of First Insulinization by Administration of Basal Insulin in Asian Patients (pts) with Type 2 Diabetes (T2D)
    Tsai, Shih-Tzer
    DIABETES, 2009, 58 : A524 - A524
  • [23] Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes
    Tan, Xueying
    Hu, Jingbo
    ANNALES D ENDOCRINOLOGIE, 2016, 77 (05) : 557 - 562
  • [24] Safety and efficacy of linagliptin in elderly patients with type 2 diabetes: evidence from 1331 individuals aged ≥65 years
    Patel, S.
    Schernthaner, G.
    Barnett, A. H.
    Emser, A.
    von Eynatten, M.
    Woerle, H. -J.
    DIABETOLOGIA, 2012, 55 : S351 - S351
  • [25] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Sawhney, Sangeeta
    Banks, Phillip L.
    Jiang, Wenjun
    Lapuerta, Pablo
    DIABETES, 2020, 69
  • [26] Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment
    Cherney, David
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Carroll, Amy K.
    Lapuerta, Pablo
    Banks, Phillip L.
    Jiang, Wenjun
    Sawhney, Sangeeta
    DIABETES, 2020, 69
  • [27] REAL WORLD TOLERABILITY AND EFFECTIVENESS OF EXENATIDE ONCE WEEKLY COMPARED TO BASAL INSULIN AMONG ELDERLY PATIENTS WITH TYPE 2 DIABETES (T2D)
    Seeger, J. D.
    Loughlin, A. M.
    Qiao, Q.
    Nunes, A. P.
    Ezzy, S.
    Yochum, L. A.
    Clifford, C. R.
    Gately, R.
    Ohman, P.
    Dore, D. D.
    VALUE IN HEALTH, 2016, 19 (07) : A668 - A668
  • [28] The Efficacy and Safety of Lixisenatide in Asian Patients with Type 2 Diabetes (T2D) Insufficiently Controlled with Basal Insulin plus /- Metformin: The GetGoal-L-C Trial
    Yang, Wenying
    Zhang, Nianxian
    Niemoeller, Elisabeth
    Shang, Shuhua
    DIABETES, 2016, 65 : A264 - A264
  • [29] Treatment Patterns and Characteristics of Patients with Type 2 Diabetes (T2D) Managed with Basal-Bolus Therapy in the
    Van Brunt, Kate
    Curtis, Bradley H.
    Chalkiadaki, Corina
    Balogh, Elemer
    Ivanyi, Tibor
    Raluy, Mireia
    Maclachlan, Sharon
    DIABETES, 2015, 64 : A696 - A697
  • [30] Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes
    Juurinen, L.
    Tiikkainen, M.
    Saltevo, J.
    Nikkila, K.
    Lanki, H.
    Leppavuori, E.
    Kock, T.
    Teikari-Myyra, T.
    Kauppinen-Makelin, R.
    Kotronen, A.
    Yki-Jarvinen, H.
    DIABETIC MEDICINE, 2009, 26 (04) : 409 - 415
12345